Primary biliary cirrhosis

被引:302
作者
Talwalkar, JA [1 ]
Lindor, KD [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
关键词
D O I
10.1016/S0140-6736(03)13808-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary biliary cirrhosis is a chronic cholestatic liver disease of adults. This disorder is characterised histologically by chronic non-suppurative destruction of interlobular bile ducts leading to advanced fibrosis, cirrhosis, and liver failure. The precise aetiopathogenesis of primary biliary cirrhosis remains unknown, although dysregulation of the immune system and genetic susceptibility both seem to be important. Affected patients are typically middle-aged women with abnormal serum concentrations of alkaline phosphatase. Presence of antimitochondrial antibody in serum is almost diagnostic of the disorder. Identification of primary biliary cirrhosis is important, because effective treatment with ursodeoxycholic acid has been shown to halt disease progression and improve survival without need for liver transplantation. However, therapeutic options for disease-related complications-including fatigue and metabolic bone disease-remain unavailable. Mathematical models have been developed that accurately predict the natural history of primary biliary cirrhosis in individuals. Despite advances in understanding of the disease, it remains one of the major indications for liver transplantation worldwide.
引用
收藏
页码:53 / 61
页数:9
相关论文
共 140 条
[91]   Tumor necrosis factor-α and transforming growth factor-β reflect severity of liver damage in primary biliary cirrhosis [J].
Neuman, M ;
Angulo, P ;
Malkiewicz, I ;
Jorgensen, R ;
Shear, N ;
Dickson, ER ;
Haber, J ;
Katz, G ;
Lindor, K .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (02) :196-202
[92]   PRIMARY BILIARY-CIRRHOSIS AND GRAVES-DISEASE [J].
NIERI, S ;
RICCARDO, GG ;
SALVADORI, G ;
SURRENTI, C .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1985, 7 (05) :434-437
[93]   Incidence of cancer in primary biliary cirrhosis: The Mayo experience [J].
Nijhawan, PK ;
Therneau, TM ;
Dickson, ER ;
Boynton, J ;
Lindor, KD .
HEPATOLOGY, 1999, 29 (05) :1396-1398
[94]   Serum antibodies to Helicobacter hepaticus and Helicobacter pylori in patients with chronic liver disease [J].
Nilsson, I ;
Lindgren, S ;
Eriksson, S ;
Wadström, T .
GUT, 2000, 46 (03) :410-414
[95]   Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen during apoptosis [J].
Odin, JA ;
Huebert, RC ;
Casciola-Rosen, L ;
LaRusso, NF ;
Rosen, A .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (02) :223-232
[96]  
PARES A, 1981, GASTROENTEROLOGY, V80, P681
[97]   Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis:: results of a double-blind controlled multicentric trial [J].
Parés, A ;
Caballería, L ;
Rodés, J ;
Bruguera, M ;
Rodrigo, L ;
García-Plaza, A ;
Berenguer, J ;
Rodríguez-Martínez, D ;
Mercader, J ;
Velicia, R .
JOURNAL OF HEPATOLOGY, 2000, 32 (04) :561-566
[98]   The association between gravidity and primary biliary cirrhosis [J].
Parikh-Patel, A ;
Gold, E ;
Utts, J ;
Gershwin, ME .
ANNALS OF EPIDEMIOLOGY, 2002, 12 (04) :264-272
[99]   Risk factors for primary biliary cirrhosis in a cohort of patients from the United States [J].
Parikh-Patel, A ;
Gold, EB ;
Worman, H ;
Krivy, KE ;
Gershwin, ME .
HEPATOLOGY, 2001, 33 (01) :16-21
[100]   Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis [J].
Pasha, T ;
Heathcote, J ;
Gabriel, S ;
Cauch-Dudek, K ;
Jorgensen, R ;
Therneau, T ;
Dickson, ER ;
Lindor, KD .
HEPATOLOGY, 1999, 29 (01) :21-26